{"id":3072,"date":"2016-05-04T06:30:00","date_gmt":"2016-05-04T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/"},"modified":"2016-05-04T06:30:00","modified_gmt":"2016-05-04T06:30:00","slug":"kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/","title":{"rendered":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)"},"content":{"rendered":"<\/p>\n<p><span>P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 3 maj beslutades bl.a. f\u00f6ljande:<\/span><\/p>\n<\/p>\n<p><span>\u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2015.<\/span><\/p>\n<\/p>\n<p><span>\u2022 Omval av Fredrik Mattsson, Erik von Schenck, Semmy R\u00fclf, G\u00f6sta Johannesson, och Folke Nilsson, samt nyval av Camilla \u00d6berg till styrelseledam\u00f6ter, i enlighet med valberedningens f\u00f6rslag. Till styrelsens ordf\u00f6rande omvaldes Fredrik Mattsson.<\/span><\/p>\n<\/p>\n<p><span>\u2022 Styrelsearvode ska utg\u00e5 med totalt ska utg\u00e5 med totalt 840 000 kronor, varav 170 000 kronor till styrelseordf\u00f6randen, 100 000 kronor vardera till \u00f6vriga styrelseledam\u00f6ter, 40 000 kronor till ordf\u00f6rande i revisionsutskottet, 40 000 kronor till ordf\u00f6rande i ers\u00e4ttningsutskottet samt 25 000 kronor till envar av \u00f6vriga ledam\u00f6ter i dessa utskott.<\/p>\n<p><\/span><\/p>\n<p><span>\u2022 Antagande av riktlinjer f\u00f6r utseende av valberedning, att g\u00e4lla tills vidare, i enlighet med valberedningens f\u00f6rslag.<\/span><\/p>\n<\/p>\n<p><span>\u2022 F\u00f6reslagna principer f\u00f6r ers\u00e4ttning och andra anst\u00e4llningsvillkor f\u00f6r bolagsledningen godk\u00e4ndes.<\/span><\/p>\n<\/p>\n<p><span>\u2022 Styrelsen bemyndigades att f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma vid ett eller flera tillf\u00e4llen besluta om<\/span><\/p>\n<\/p>\n<p><span>nyemission av h\u00f6gst 2\u00a0150\u00a0000 aktier motsvarande knappt 10 procent av det totala antalet aktier och r\u00f6ster i bolaget.<\/span><\/p>\n<\/p>\n<p><span>\u2022 F\u00f6reslagen emission av totalt 212\u00a0000 teckningsoptioner med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier godk\u00e4ndes. Teckningsoptionerna ska erbjudas samtliga anst\u00e4llda i XVIVO Perfusion AB. Vid fullt utnyttjande av optionsr\u00e4tterna kommer aktiekapitalet att \u00f6ka med cirka 5\u00a0418 kronor motsvarande en utsp\u00e4dning om cirka 1 procent av det totala antalet aktier och r\u00f6ster i bolaget. <\/span><\/p>\n<\/p>\n<p><span>G\u00f6teborg 4 maj 2016<br \/><\/span>XVIVO Perfusion AB (publ)<br \/>Styrelsen<\/p>\n<div class=\"mfn-footer\">\n<p><span>Fr\u00e5gor h\u00e4nvisas till:<\/span><br \/><span>Fredrik Mattsson, styrelsens ordf\u00f6rande, telefon 08-614 00 20<\/span><br \/><span>Christoffer Rosenblad, CFO, telefon +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com<\/span><\/p>\n<p><span>Informationen l\u00e4mnades f\u00f6r publicering den\u00a04 maj 2016 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 3 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2015. \u2022 Omval av&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3072","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-info"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 3 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2015. \u2022 Omval av...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\\\/\",\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-05-04T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/","og_locale":"en_US","og_type":"article","og_title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","og_description":"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 3 maj beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2015. \u2022 Omval av...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/","name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-05-04T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}